Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... Nevertheless, the Danish pharma continues to recognize the importance of its production network, with the company noting in its ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Novo Nordisk reported $40.5 billion in sales for ... in a race with rival drugmakers to deliver GLP-1s in pill form. The pharmaceutical giant and maker of Ozempic and Wegovy reported better ...

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC ...

Dual agonists are proving to be especially promising candidates, and many pharmaceutical companies have created some versions. Novo Nordisk recently reported data from a phase 1b/2a clinical trial ...